Letter to the EditorResponse to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?
Under an Elsevier user license
open archive
Cited by (0)
Disclosure: Dr. Cooper is an advisory board member and has received honoraria for lectures from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc. The remaining authors declare no conflict of interest.
© 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.